Weekly NIH Funding Opportunities and Notices
NIH Guide for Grants and Contracts
December 22, 2017
Table of Contents (TOC)
Web Version

Notices

- Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Projects (NOT-OD-17-071) National Institutes of Health

- Maintaining Integrity in NIH Peer Review: Responsibilities and Consequences (NOT-OD-18-115) National Institutes of Health


- FINDINGS OF RESEARCH MISCONDUCT (NOT-OD-18-121) National Institutes of Health

- Notice of Change to Award Information in RFA-AI-17-040 "Cooperative Centers on Human Immunology (U19 Clinical Trial Optional" (NOT-AI-18-007) National Institute of Allergy and Infectious Diseases

- Notice of Participation of National Institute of Allergy and Infectious Diseases (NIAID) on PAR-18-333" Understanding the Early Development of the Immune System (R01 - Clinical Trial Not Allowed)" (NOT-AI-18-008) National Institute of Allergy and Infectious Diseases

- Notice of NIAMS' Participation in PA-18-375 "Mentored Patient-Oriented Research Career Development Award (Parent K23 -Independent Clinical Trial Not Allowed)" (NOT-AR-18-010) National Institute of Arthritis and Musculoskeletal and Skin Diseases

- Notice of NIAMS' Participation in PA-18-394 " Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - No Independent Clinical Trials)" (NOT-AR-18-011) National Institute of Arthritis and Musculoskeletal and Skin Diseases

- Notice of Correction to Key Dates for PAR-18-022 "Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)" (NOT-CA-18-030) National Cancer Institute
• NIH Applicant Assistance Program (AAP) for New or Previously Unawarded Small Businesses
  (NOT-CA-18-031)
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute of Neurological Disorders and Stroke

• Notice of Correction to PA-18-517, "Innovation Corps (I-Corps) at NIH Program for NIH and
  CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)"
  (NOT-CA-18-034)
  National Cancer Institute

• Notice of NIDDK's Participation in PAR-18-189 "Multidisciplinary Studies of HIV/AIDS and
  Aging (R01 Clinical Trial Optional)"
  (NOT-DK-18-005)
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of NIDDK's Participation in PAR-18-190 "Multidisciplinary Studies of HIV/AIDS and
  Aging (R21 Clinical Trial Optional)"
  (NOT-DK-18-006)
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice to Clarify the Types of Clinical Trials NIBIB Will Supported Under PAR-18-208
  Bioengineering Research Partnerships (U01 Clinical Trial Optional)
  (NOT-EB-18-004)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-397
  "NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Required"
  (NOT-ES-18-006)
  National Institute of Environmental Health Sciences

• Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-395
  "Mentored Quantitative Research Development Award (Parent K25 - Clinical Trial Required)"
  (NOT-ES-18-007)
  National Institute of Environmental Health Sciences

• Notice of NEI Participation in PAR-18-501 "BRAIN Initiative: Development, Optimization, and
  Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44
  Clinical Trial Not Allowed)"
  (NOT-EY-18-003)
  National Eye Institute

• Notice of NEI Participation in PAR-18-515 "BRAIN Initiative: Development, Optimization, and
  Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42
  Clinical Trial Not Allowed)"
  (NOT-EY-18-004)
  National Eye Institute

• Notice of Correction to Eligibility Information in PAR-17-190 "Maximizing Investigators'
  Research Award for Early Stage Investigators (R35)"
  (NOT-GM-18-013)
  National Institute of General Medical Sciences
- Notice of Changes in PAR-16-149 "Archiving and Documenting Child Health and Human Development Data Sets (R03)"
  (NOT-HD-17-028)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Notice of NIMHD Participation in RFA-HL-19-007 "Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) (U01 Clinical Trial Not Allowed)"
  (NOT-MD-18-003)
  National Institute on Minority Health and Health Disparities

- Notice of NIMHD Participation in RFA-HL-19-008 "Limited Competition: Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) (U01 Clinical Trial Not Allowed)"
  (NOT-MD-18-004)
  National Institute on Minority Health and Health Disparities

- Notice of NINDS Policy for Submission of Applications and Participation in PA-18-345 "NIH Research Project Grant (Parent R01) - Clinical Trial Required". NINDS Only accepts Clinical Trial Applications Proposing Mechanistic Studies for Clinical Trial Parent R01
  (NOT-NS-18-011)
  National Institute of Neurological Disorders and Stroke

- Notice of Clarification of NINDS Statement of interest for "Bioengineering Research Partnerships (BRP) (U01 Clinical Trial Optional)"
  (NOT-NS-18-029)
  National Institute of Neurological Disorders and Stroke

- Notice of NINDS Withdrawal from Participation in PA-18-286 "Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)"
  (NOT-NS-18-030)
  National Institute of Neurological Disorders and Stroke

- Notice of Pre-Application Webinar for the Common Fund Human Biomolecular Atlas Program (HuBMAP) RFAs (RFA-RM-17-025, RFA-RM-17-027)
  (NOT-RM-18-008)
  The Common Fund/Office of Strategic Coordination

- Notice of Change to Receipt Date on NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3 Clinical Trials Not Allowed) (RFA-TR-18-001)
  (NOT-TR-18-014)
  National Center for Advancing Translational Sciences
Requests for Applications

- Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimer's Disease (R01 - Clinical Trial Not Allowed) (RFA-AG-18-022)
  National Institute on Aging
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed) (RFA-AG-18-025)
  National Institute on Aging
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- Limited Competition: Revision Applications for International Centers of Excellence for Malaria Research (U19 Clinical Trial Optional) (RFA-AI-17-044)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required) (RFA-DA-18-017)
  National Institute on Drug Abuse
  Application Receipt Date(s): April 13, 2018 and November 15, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01-Clinical Trial Not Allowed) (RFA-DA-18-023)
  National Institute on Drug Abuse
  Application Receipt Date(s): April 17, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01-Clinical Trial Optional)
  (RFA-DK-17-017)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 20, 2018 and, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)
  (RFA-DK-17-018)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 20, 2018; February 21, 2019; February 21, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR)
  (R43/R44- Clinical Trial Not Allowed)
  (RFA-DK-17-029)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization.

• Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)
  (RFA-DK-17-030)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization.

• Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01 Clinical Trials Not Allowed)
  (RFA-HL-19-007)
  National Heart, Lung, and Blood Institute
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Application Receipt Date(s): May 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• Limited Competition: Clinical Research Sites for MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01-Clinical Trials Not Allowed) (RFA-HL-19-008)
  National Heart, Lung, and Blood Institute
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Application Receipt Date(s): May 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

• BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required) (RFA-NS-18-021)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required) (RFA-NS-18-022)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February
21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM local time of applicant organization.

- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 - Clinical Trial Required) *(RFA-NS-18-023)*
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trials Not Allowed) *(RFA-RM-17-025)*
  The Common Fund/Office of Strategic Coordination
  Application Receipt Date(s): March 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed) *(RFA-RM-17-027)*
  The Common Fund/Office of Strategic Coordination
  Application Receipt Date(s): March 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed) *(RFA-TR-18-005)*
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)  
  (RFA-TR-18-006)  
  National Center for Advancing Translational Sciences  
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed)  
  (RFA-TW-17-001)  
  John E. Fogarty International Center  
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Program Announcements

• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)  
  (PA-18-347)  
  National Institute of Nursing Research  
  National Institute on Aging  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)  
  (PA-18-348)  
  National Institute of Nursing Research  
  National Institute on Aging  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Self-Management for Health in Chronic Conditions (R01 Clinical Trial Optional)  
  (PA-18-376)  
  National Institute of Nursing Research  
  National Institute on Aging  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional) (PA-18-377)  
National Institute of Nursing Research  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional) (PA-18-381)  
National Institute of Nursing Research  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Self-Management for Health in Chronic Conditions (R21 Clinical Trial Optional) (PA-18-384)  
National Institute of Nursing Research  
National Institute on Aging  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Innovative Questions in Symptom Science and Genomics (R15 Clinical Trial Not Allowed) (PA-18-471)  
National Institute of Nursing Research  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• Personalized Strategies to Manage Symptoms of Chronic Illness (R15 Clinical Trial Not Allowed) (PA-18-472)  
National Institute of Nursing Research  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R15 Clinical Trial Not Allowed) (PA-18-473)  
National Institute of Nursing Research  
National Institute on Aging  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow
adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Self-Management for Health in Chronic Conditions (R15 Clinical Trial Not Allowed)** *(PA-18-474)*
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Community Partnerships to Advance Research (CPAR) (R15 Clinical Trial Not Allowed)** *(PA-18-475)*
  National Institute of Nursing Research
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 - Clinical Trial Optional)** *(PA-18-507)*
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first due date for this FOA is June 5, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 - Clinical Trial Optional)** *(PA-18-508)*
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first due date for this FOA is June 16, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)** *(PA-18-517)*
  National Cancer Institute
  National Center for Advancing Translational Sciences
  National Center for Emerging and Zoonotic Infectious Diseases
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed) (PA-18-525)
National Institute of Allergy and Infectious Diseases
Application Receipt/Submission Date(s): March 5, 2018, by 5:00 PM local time of applicant organization.

Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed) (PA-18-529)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed) (PA-18-531)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed) (PA-18-532)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01 - Clinical Trial Optional)  
(PA-18-545)
National Institute on Aging
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
_Eunice Kennedy Shriver_ National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Science Research
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed)  
(PAR-18-505)
National Institute of Mental Health
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional)  
(PAR-18-506)
_Eunice Kennedy Shriver_ National Institute of Child Health and Human Development
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional)  
(PAR-18-509)
National Institute on Drug Abuse
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01)  
(PAR-18-510)
National Institute on Drug Abuse
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional) (PAR-18-511)
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development

Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimer's Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed) (PAR-18-512)
  National Institute on Aging
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) (PAR-18-513)
  National Institute on Aging

Application Receipt/Submission Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequently, standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

• Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimer's Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed) (PAR-18-514)
  National Institute on Aging
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed) (PAR-18-516)
  National Institute on Aging

Application Receipt/Submission Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates for new applications: June 8, 2018; October 9, 2018; February 8, 2019; June 7, 2019; October 7, 2019; February 7, 2020; June 7, 2020; and October 7, 2020, by 5:00 PM local time of the applicant organization. Due dates for resubmission and revision applications: July 9, 2018; November 7, 2018; March 7, 2019; July 7, 2019; November 7, 2019; March 7, 2020; July 7, 2020; and November 7, 2020, by 5:00 PM local time of applicant organization.
- Sensory and motor system changes as predictors of preclinical Alzheimer's disease (R01 - Clinical Trial Not Allowed) (PAR-18-519)

  National Institute on Aging

  Application Receipt/Submission Date(s): New: March 26, 2018; June 6, 2018; October 7, 2018; February 7, 2019; June 7, 2019; October 7, 2019; February 7, 2020; June 8, 2020; and October 8, 2020, by 5:00 PM local time of the applicant organization. Resubmission/Revision: July 7, 2018; November 7, 2018; March 7, 2019; July 8, 2019; November 7, 2019; March 6, 2020; July 7, 2020; and November 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) (PAR-18-521)

  National Eye Institute

  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) (PAR-18-522)

  National Eye Institute

  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required) (PAR-18-523)

  National Eye Institute

  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32 - Clinical Trial Not Allowed) (PAR-18-524)

  National Institute on Aging

  Application Receipt/Submission Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequently, standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)  
(PAR-18-527)  
National Institute on Drug Abuse  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• NeuroNEXT Clinical Trials (U01 - Clinical Trial Optional)  
(PAR-18-528)  
National Institute of Neurological Disorders and Stroke  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)  
(PAR-18-530)  
National Cancer Institute  
National Institute of Biomedical Imaging and Bioengineering  
National Institute of Diabetes and Digestive and Kidney Diseases  
Application Receipt/Submission Date(s): The first due date for all types of applications allowed for this FOA is March 8, 2018. Thereafter Standard dates apply, by 5:00 PM local time of applicant organization, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional)  
(PAR-18-533)  
National Institute on Deafness and Other Communication Disorders  
Application Receipt/Submission Date(s): June 19, 2018; February 20, 2019; October 18, 2019; June 18, 2020; February 22, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01)  
(PAR-18-534)  
National Institute of Neurological Disorders and Stroke  
Application Receipt/Submission Date(s): February 15, 2018; August 17, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)  
  (PAR-18-538)  
  National Institute on Aging  
  Application Receipt/Submission Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates are June 20, 2018; February 20, 2019; June 20, 2019; February 20, 2020; and June 22, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- International Research Scientist Development Award (IRSDA) (K01) - Independent Clinical Trial Not Allowed  
  (PAR-18-539)  
  John E. Fogarty International Center  
  National Cancer Institute  
  Application Receipt/Submission Date(s): March 7, 2018; March 7, 2019; March 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- International Research Scientist Development Award (IRSDA) (K01) - Independent Clinical Trial Required  
  (PAR-18-540)  
  John E. Fogarty International Center  
  National Cancer Institute  
  Application Receipt/Submission Date(s): March 7, 2018; March 7, 2019; March 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional  
  (PAR-18-541)  
  National Institute of Neurological Disorders and Stroke  
  National Center for Complementary and Integrative Health  
  National Eye Institute  
  National Institute on Aging  
  National Institute on Alcohol Abuse and Alcoholism  
  Eunice Kennedy Shriver National Institute of Child Health and Human Development  
  National Institute on Drug Abuse  
  National Institute of Dental and Craniofacial Research  
  National Institute of Mental Health  
  Application Receipt/Submission Date(s): February 7, 2018, August 9, 2018, February 9, 2019, August 9, 2019, February 11, 2020, by 5:00 PM local time of applicant organization.
• NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional) (PAR-18-542)
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): February 20, 2018, July 18, 2018, February 13, 2019, July 18, 2019, February 13, 2020, and July 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional) (PAR-18-543)
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): February 20, 2018, July 18, 2018, February 13, 2019, July 18, 2019, February 13, 2020, and July 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional) (PAR-18-544)
  National Institute on Aging
  Application Receipt/Submission Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates are June 8, 2018; February 8, 2019; June 8, 2019; February 7, 2020; and June 8, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates, including new, renewal, resubmission, and revision applications. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3) - Clinical Trial Optional (PAR-18-546)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  Application Receipt/Submission Date(s): February 7, 2018, August 9, 2018, February 9, 2019, August 9, 2019, February 11, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
- **NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required**
  (PAR-18-547)
  National Institute of Dental and Craniofacial Research
  Application Receipt/Submission Date(s): New applications - February 23, June 6, and October 4 of 2018; February 6, June 6 and October 8 of 2019; February 6, June 8, and October 6 of 2020 by 5:00 PM local time of applicant organization. Revised applications - July 6 and November 6 of 2018; March 6, July 8 and November 6 of 2019; June 6, July 7 and November 6 of 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)**
  (PAR-18-548)
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): March 14, 2018; July 18, 2018; February 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization.

- **Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)**
  (PAR-18-549)
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): March 14, 2018; July 18, 2018; February 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization.

- **Analytical Validation of Candidate Biomarkers for Neurological Disease (U01 Clinical Trial Optional)**
  (PAR-18-550)
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): March 14, 2018; July 18, 2018; February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **Partnership for Aging and Cancer Research (U01 - Clinical Trial Not Allowed)**
  (PAR-18-552)
  National Cancer Institute
  National Institute on Aging
  Application Receipt/Submission Date(s): June 8, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.